0.017
0.00 (-8.56%)
| Previous Close | 0.019 |
| Open | 0.018 |
| Volume | 96,418 |
| Avg. Volume (3M) | 520,307 |
| Market Cap | 1,296,898 |
| Price / Earnings (TTM) | 0.190 |
| Price / Sales | 0.880 |
| Price / Book | 33.49 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 - 22 Aug 2025 |
| Operating Margin (TTM) | -18,553.67% |
| Diluted EPS (TTM) | 0.090 |
| Quarterly Revenue Growth (YOY) | -96.40% |
| Current Ratio (MRQ) | 0.140 |
| Levered Free Cash Flow (TTM) | 1.67 M |
| Return on Assets (TTM) | -62.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | CAN B CORP. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
Can B Corp., a health and wellness company, develops, manufactures, and sells hemp derived products in the United States. The company provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and lifestyle products. It sells its products under the Canbiola, Nu Wellness, Seven Chakras, and Pure Leaf Oil brands through medical professionals, website, and vending machines. The company also produces industrial hemp, and processes hemp biomass, isolate, and isomers, such as CBN, CBG, delta-8, and delta-10; and manufactures and sells durable medical equipment. The company was formerly known as Canbiola Inc. and changed its name to Can B Corp. in February 2020. Can B Corp. was incorporated in 2005 and is based in Hicksville, New York. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.48% |
| % Held by Institutions | 0.98% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Apr 2025 | Announcement | Can B Corp.'s Nascent Pharma Hires Fox Rothschild to Defend and Monetize Its Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |